Recruiting

CAR-T Cells

Sponsor:

Medical College of Wisconsin

Code:

NCT03375619

Conditions

Chronic Lymphocytic Leukemia

Lymphomas Non-Hodgkin's B-Cell

Lymphoma, Small Lymphocytic

Mantle Cell Lymphoma

Central Nervous System Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Long-Term Follow-Up of Participants who Received CAR-T cells

Study Details

Brief summary:

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:

Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Conditions

Chronic Lymphocytic Leukemia

Lymphomas Non-Hodgkin's B-Cell

Lymphoma, Small Lymphocytic

Mantle Cell Lymphoma

Central Nervous System Lymphoma

Study ID

NCT03375619

Start date

Dec 1, 2017

Status verified date

Nov, 2025

Completion date

Jan 1, 2035

Anticipated

Primary completion date

Jan 1, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

Exclusion Criteria:

  • There are no exclusion criteria for this study.

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants who received CAR-T cells.

Participants who received CAR-T cells at Froedtert Hospital \& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).

Interventions

Long-Term Follow-Up of Participants who Received CAR-T cells

No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Primary outcome measure

  • Change from baseline in the incidence of a new malignancy at 5 years. [ Time Frame: Baseline to five years. ]
  • Change from baseline in the incidence of a new malignancy at 10 years. [ Time Frame: Baseline to 10 years. ]
  • Change from baseline in the incidence of a new malignancy at 15 years. [ Time Frame: Baseline to 15 years. ]

Central Contacts and Locations

Central contacts

Medical College of Wisconsin Clinical Cancer Center

414-805-8900cccto@mcw.edu

Locations

Froedtert Hospital & Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Cancer Center Clinical Trials Office

414-805-8900cccto@mcw.edu

More Information

Sponsor

Medical College of Wisconsin

Last update posted

Nov 10, 2025

Last verified

Nov, 2025

Keywords

  • CAR-T Cell Therapy
  • chimeric antigen receptor

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Medical College of Wisconsin on 2025-11-10.